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Abstract
Background: Sub-cortical vascular ischaemia is the second most common etiology contributing to cognitive
impairment in older adults, and is frequently under-diagnosed and under-treated. Although evidence is mounting
that exercise has benefits for cognitive function among seniors, very few randomized controlled trials of exercise
have been conducted in populations at high-risk for progression to dementia. Aerobic-based exercise training may
be of specific benefit in delaying the progression of cognitive decline among seniors with vascular cognitive
impairment by reducing key vascular risk factors associated with metabolic syndrome. Thus, we aim to carry out a
proof-of-concept single-blinded randomized controlled trial primarily designed to provide preliminary evidence of
efficacy aerobic-based exercise training program on cognitive and everyday function among older adults with mild
sub-cortical ischaemic vascular cognitive impairment.
Methods/Design: A proof-of-concept single-blinded randomized trial comparing a six-month, thrice-weekly,
aerobic-based exercise training group with usual care on cognitive and everyday function. Seventy older adults
who meet the diagnostic criteria for sub-cortical ischaemic vascular cognitive impairment as outlined by Erkinjuntti
and colleagues will be recruited from a memory clinic of a metropolitan hospital. The aerobic-based exercise
training will last for 6 months. Participants will be followed for an additional six months after the cessation of
exercise training.
Discussion: This research will be an important first step in quantifying the effect of an exercise intervention on
cognitive and daily function among seniors with sub-cortical ischaemic vascular cognitive impairment, a
recognized risk state for progression to dementia. Exercise has the potential to be an effective, inexpensive, and
accessible intervention strategy with minimal adverse effects. Reducing the rate of cognitive decline among seniors
with sub-cortical ischaemic vascular cognitive impairment could preserve independent functioning and health
related quality of life in this population. This, in turn, could lead to reduced health care resource utilization costs
and avoidance of early institutional care.
Trial Registration: ClinicalTrials.gov Protocol Registration System: NCT01027858.
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Cerebrovascular disease is the second most common
etiology contributing to dementia in older adults [1-4]
and may be the most under-diagnosed and yet most
treatable form of cognitive dysfunction in older adults
[5]. Vascular cognitive impairment is defined as the loss
of cognitive function resulting from ischaemic, ischae-
mic-hypoxic, or hemorrhagic brain lesions as a result of
cerebrovascular disease and cardiovascular pathologic
changes. As vascular cognitive impairment is predomi-
nantly a sub-cortical frontal form of cognitive disorder
with prominent executive dysfunction [6], it directly
impairs everyday function [7], such as managing
finances, transportation, or the telephone. Taken
together, vascular cognitive impairment has the potential
to severely impact the ability to function autonomously
within society [8].
A number of epidemiological studies suggest that
modification of vascular risk factors, such as hyperten-
sion, diabetes mellitus, and hypercholesterolemia may be
helpful in slowing down the progression of vascular cog-
nitive impairment [9-12]. Hence, one promising
approach to delay the progression of vascular cognitive
impairment is aerobic-based exercise training. Critically,
evidence is mounting that exercise has benefits for cog-
nitive function among seniors. Aerobic-based exercise
training may be of specific benefit in slowing the pro-
gression of cognitive decline among seniors with vascu-
lar cognitive impairment by reducing key vascular risk
factors associated with metabolic syndrome. Aerobic
exercise may also act specifically on disease pathophy-
siology [13], for example, by improving capillarization or
modulating brain neurotrophic factors [14-16], and may
even decrease brain amyloid load in the brain [17].
Finally, aerobic-based exercise training as an interven-
tion strategy for individuals with vascular cognitive
impairment is attractive as it could be delivered at a
population-level.
The growing consensus is that small vessel diseases
have an important role in vascular cognitive impairment
[18,19]. Small vessel disease often presents as unde-
tected “covert” strokes in the sub-cortical white matter.
Compared to other forms of vascular cognitive impair-
ment, the sub-cortical ischaemic vascular disease sub-
type is a more homogenous form of the disease with a
more predictable outcome [20]. While mild Sub-cortical
Ischaemic Vascular Cognitive Impairment (SIVCI)
describes those individuals whose symptoms are not
associated with substantial functional impairment [18],
persons with mild SIVCI have a high risk of progression
to dementia [18,21]. Seniors with mild SIVCI are also at
risk for executive dysfunction [18], and subsequently at
risk for decline in everyday function (i.e., ability to
perform instrumental activities of daily living [ADLs])
[7]. Instrumental ADLs refer to capacities that are
required for autonomous function within society [8]; the
ability to perform instrumental ADLs is a key aspect of
functional independence and health related quality of
life [8]. Thus, persons with mild SIVCI represent an
ideal target population for intervention strategies, as
preservation of their cognitive and functional status will
likely maintain and prolong their ability to live indepen-
dently and with quality. To our knowledge, no rando-
mized controlled trial has assessed the effect of aerobic-
based exercise training on cognitive and everyday func-
tion among seniors with mild SIVCI. Thus, we aim to
carry out a proof-of-concept single-blinded randomized
controlled trial primarily designed to provide prelimin-
ary evidence of efficacy of a six-month, thrice-weekly,
aerobic-based exercise training program on cognitive
and everyday function among older adults with mild
SIVCI. In addition, this proof-of-concept study will aim
to explore the effect of aerobic-based exercise training
on: 1) serum glucose, hemoglobin A1c, and lipids; 2)
inflammatory biomarkers; 3) physical function; 4) health
related quality of life; and 5) health resource utilization.
Finally, this study will demonstrate the feasibility of deli-
vering the intervention in this population, determine the
recruitment rate, determine the rate of withdrawal, and
provide estimates of the variances, co-variances and
effect sizes of the proposed outcome measures to inform
the sample size for a larger definitive trial.
Methods/Design
Design Outline
We will conduct a six-month proof-of-concept single-
blinded randomized trial and follow our study cohort
for an additional six months of follow-up (see Figure 1).
Recruitment
We will recruit seniors with mild SIVCI through the
University of British Columbia Hospital Clinic for Alz-
heimer Disease and Related Disorders (UBCH-CARD).
All individuals who receive care at the UBCH-CARD
have the option to sign a consent form providing access
to their records for research purposes and indicating
their willingness to be approached for research studies.
One trained research assistant will review the charts of
patients at the UBCH-CARD who have expressed inter-
ests to participate in research studies. Clinicians at the
UBCH-CARD will also be informed of this study and
they will assist in recruitment by flagging the charts of
their current patients who may qualify for this study to
our research assistants. Those who appear eligible based
on detailed chart review will be mailed an information
package regarding the study, including the consent form.
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hour consent and screening session will be arranged.
Once informed consent is obtained, we will perform the
screening tests. Those who remain eligible after the
screening session and who later provide written recom-
mendation from their physician indicating their appro-
priateness to participate in an aerobic-based exercise
training program will proceed to baseline assessments.
Eligibility
We will recruit individuals who fulfill the diagnostic cri-
teria for SIVCI as outlined by Erkinjuntti and colleagues
[22], which requires the presence of both cognitive syn-
drome (as defined in Section A below) and small vessel
ischaemic disease (as defined in Section B below).
A. Cognitive Syndrome defined as:
1. Dysexecutive Syndrome: Some impairment in goal
formulation, initiation, planning, organizing, sequencing,
executing, set-shifting and maintenance, or abstracting.
2. Memory Deficit: Some impairment in recall in the
presence of relatively intact recognition and benefit
from cueing.
3. Progression: Deterioration of A1 and A2 from a pre-
vious higher level of functioning that are not per se
interfering with complex occupational and social
activities.
B. Small Vessel Ischaemic Disease defined as:
1. Evidence of relevant cerebrovascular disease by
brain imaging (in the last 12 months) defined as the
presence of both:
i. Periventricular and deep white matter lesions: Pat-
chy areas of low attenuation (intermediate density
between that of normal white matter and that of
intraventricular cerebrospinal fluid) or diffuse sym-
metrical areas of low attenuation with ill defined
margins extending to the centrum semiovale, plus at
least one lacunar infarct (correlating to the white
Figure 1 Overview of the flow of participants through the Promotion of the Mind Through Exercise (PROMoTE) Trial.
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vascular Health Study) [23,24]; and
ii. Absence of cortical and/or cortico-sub-cortical
non-lacunar territorial infarcts and watershed
infarcts, haemorrhages indicating large vessel disease,
signs of normal pressure hydrocephalus, or other
specific causes of white matter lesions (e.g., multiple
sclerosis, leukodystrophies, sarcoidosis, brain irradia-
tion, etc).
2. Presence or a history of neurological signs as evi-
dence for cerebrovascular disease such as lower facial
weakness, Babinski sign, sensory deficit, dysarthria, gait
disorder, or extrapyramidal signs consistent with sub-
cortical brain lesion(s).
In addition, individuals must meet the following inclu-
sion criteria: 1) Montreal Cognitive Assessment (MoCA)
[25] score less than 26 at screening; 2) Mini-Mental
State Examination (MMSE) [26] score of ≥ 20 at screen-
ing; 3) Community-dwelling; 4) Live in Metro Vancou-
ver; 5) Have a caregiver, family member, or friend who
interacts with him/her on a weekly basis; 6) Able to
comply with scheduled visits, treatment plan, and other
trial procedures; 7) Must be able to read, write, and
speak English in which psychometric tests are provided
with acceptable visual and auditory acuity; 8) Stable on
a fixed dose of cognitive medications (e.g., donepezil,
galantamine, rivastigmine, memantine, etc.) that is not
expected to change during the 12-month study period,
or, if they are not on any of these medications, they are
not expected to start them during the 12-month study
p e r i o d ;9 )P r o v i d eap e r s o n a l l ys i g n e da n dd a t e d
informed consent document indicating that the indivi-
dual (or a legally acceptable representative) has been
informed of all pertinent aspects of the trial. In addition,
an assent form will be provided at baseline and again at
regular intervals; 10) Able to walk independently; and
11) Must be in sufficient health to participate in the
study’s aerobic-based exercise training program. This
will be based on medical history, vital signs, physical
examination by study physicians, and written recom-
mendation by family physician indicating one’s appropri-
ateness to participate in an aerobic-based exercise
training program.
The exclusion criteria are: 1) Absence of relevant
small vessel ischaemic lesions on an existing brain com-
puted tomography (CT) or magnetic resonance imaging
(MRI); 2) Diagnosed with another type of neurodegen-
erative (e.g. AD) or neurological condition (e.g., multiple
sclerosis, Parkinson’s disease, etc.) that affects cognition
and mobility; 3) At high risk for cardiac complications
during exercise and/or unable to self-regulate activity or
to understand recommended activity level (i.e., Class C
of the American Heart Risk Stratification Criteria); 4)
Have clinically significant peripheral neuropathy or
severe musculoskeletal or joint disease that impairs
mobility; 5) Taking medications that may negatively
affect cognitive function, such as anticholinergics,
including agents with pronounced anticholinergic prop-
erties (e.g., amitriptyline), major tranquilizers (typical
and atypical antipsychotics), and anticonvulsants (e.g.,
gabapentin, valproic acid, etc.); or 6) Planning to partici-
pate, or already enrolled in, a clinical drug trial concur-
rent to this study.
Ethical approval has been obtained from the Vancou-
ver Coastal Health Research Institute (V07-01160) and
the University of British Columbia’s Clinical Research
Ethics Board (H07-01160).
Sample Size
Prior to launching a definitive randomized controlled
trial, it is essential that the feasibility of conducting such
a trial be demonstrated. A sample for a definitive study
with multiple end-points and outcome variables will
require several hundred participants and warrant a
multi-site study. Given that no study has examined the
effect of exercise on cognitive function in SIVCI, we
have selected a sample size of 30 participants per group.
Studies have suggested a standard deviation of change
of 6 to 7 [27-29] in Alzheimer Disease Assessment Scale
Cognitive (ADAS-Cog) scores among individuals with
vascular cognitive impairment. We highlight that a
recent exercise trial among seniors at risk for AD with
ADAS-Cog as the primary outcome measure demon-
strated an effect size of 0.60 [30]. Thus, assuming an
alpha of 0.05, 30 participants per group will provide a
power of 0.75 to 0.80. We estimate a drop-out rate of
10% during a 12-month period. Hence, we are aiming to
recruit 35 participants per group (i.e., 70 participants in
total) which will accommodate a conservative 15% drop-
out rate.
Measurements
Baseline measurements will be obtained prior to rando-
mization. There will be three measurement sessions:
baseline, 6 months, and 12 months (Figure 1). Out-
comes will be assessed by trained assessors blinded to
group allocation.
Screening Session
For the screening session, we will administer the Physi-
cal Activity Readiness Questionnaire (PAR-Q) [31], a
screening measure of physical readiness for exercise.
Global cognitive function will be assessed using the
MMSE [26] and the MoCA [25].
Descriptors
Using a wall mounted stadiometer, standing height will
be measured as stretch stature to the 0.1 cm per stan-
dard protocol. Weight will be measured twice to the 0.1
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socioeconomic status will be ascertained by a question-
naire. Participants will undergo a clinical assessment
with neurologist and study physicians (G-YRH and PL)
at baseline to confirm current health status and eligibil-
ity for study, including clinical impressions of overall
cognitive and functional status. The Neuropsychiatric
Inventory (NPI), an informant-rated instrument, will be
used to evaluate behavioural and neuropsychiatric symp-
toms [32].
Physical activity, not including the study-assigned
exercise classes, will be determined by the valid and reli-
able Physical Activities Scale for the Elderly (PASE)
questionnaire [33,34]. Designed for those aged 65 years
and older, participants use a 12-item scale to self-report
the average number of hours per day spent participating
in leisure, household, and occupational physical activ-
ities over the previous seven-day period. Accounting for
extracurricular physical activities throughout the rando-
mized trial is essential to ascertain the specific effects of
the delivered interventions on cognition and function.
Primary Outcomes
Cognitive Function We will assess cognitive function
using the cognitive section of the Alzheimer Disease
Assessment Scale (ADAS-Cog) [35]. The scale consists
of 11 brief cognitive tests assessing memory, language,
and praxis. Scores range from 0 to 70, with higher
scores indicating greater severity of cognitive impair-
ment. The ADAS-Cog has been a significant outcome
measure in numerous trials with AD [27,36,37] but also
with vascular dementia [29,38]. The ADAS-Cog has
marked advantages as an outcome measure, based on its
substantial data confirming both reliability and validity
and its use in measuring longitudinal change together
with sensitivity to treatment effects [39].
Global Executive Function Because executive dysfunc-
tion is common among those with SIVCI [6], we will
use the Executive Interview (EXIT-25) [40] to assess
global executive function. The EXIT 25 provides a stan-
dardized clinical assessment of executive functions. It
contains 25 items designed to elicit signs of frontal sys-
tem pathology. Performance on the EXIT25 correlates
well with standard neuropsychological tests of executive
functions. The EXIT25 scores range from 0 to 50, with
high scores indicating impaired global executive func-
tion. A cut point of 15 out of 50 is recommended [40].
Everyday FunctionBecause executive dysfunction is
associated with impaired everyday function [7], we will
use the ADCS-ADL to assess the ability to perform
everyday activities of daily living [41]. The ADCS-ADL
is a 23-item informant-rated questionnaire that mea-
sures, in a range of 0 to 78, an individual’sp e r f o r m a n c e
of activities of daily living.
Secondary Outcomes
Blood Biomarkers Serum glucose, Hgb A1c, and lipid
level will be measured by conventional methods. Serum
HSC, CRP, and IL-6 will be determined by standard
ELISA methods [42].
Physical Function Physical function will be assessed
using a three-instrument performance battery that
includes:
1) Six-Minute Walk
This is a walking test of physical status to assess gen-
eral cardiovascular capacity in seniors [43]. The total
distance walked in meters in six minutes is recorded in
meters.
2) Balance and Mobility
General balance and mobility will be assessed with the
National Institute on Aging (NIA) Balance Scale [44].
For this Scale, participants are assessed on performances
of standing balance, walking, and sit-to-stand. Each
component is rated out of four points, for a maximum
of 12 points. Poor performance on this scale predicts
subsequent disability [44].
3) Physiological Falls Risk
We will use the Physiological Profile Assessment
(PPA)
© [45] (Prince of Wales Medical Research Insti-
tute, Randwick, Sydney, NSW, Australia) to assess for
physiological falls risk. The PPA is a valid and reliable
tool for assessing fall risk in older people. Based on the
performance of five physiological domains (postural
sway, hand reaction time, quadriceps strength, proprio-
ception, and edge contrast sensitivity), the PPA com-
putes a fall risk score for each individual and this
measure has a 75% predictive accuracy for falls in older
people [45]. A PPA z-score of 0-1 indicates mild risk, 1-
2 indicates moderate risk, 2-3 indicates high risk, and 3
and above indicates marked risk [46].
4) Quality of Life
We will evaluate health related quality of life using the
EuroQol 5D (EQ-5D) – a preference-based generic uti-
lity instrument that provides weightings for quality
adjusted life year (QALYs). QALYs are defined as the
benefit of a health intervention in terms of time in a
series of quality-weighted health states, in which the
quality weights reflect the desirability of living in the
state, typically from “perfect” health (weighted 1.0) to
dead (weighted 0.0) [47]. QALYs are calculated based
on the quality of life of a patient (measured using health
utilities) in a given health state and the time spent in
that health state. The EQ-5D captures 243 unique
health states based on the following domains: 1) mobi-
lity; 2) self-care; 3) usual activities; 4) pain and 5) anxi-
e t yo rd e p r e s s i o n .W ew i l lc a l c u l a t eQ A L Y su s i n gt h e
health state utility values from the EQ-5D to determine
if there is a statistically significant difference in the
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receiving the aerobic-based training compared with
those who are not.
5) Health Resource Utilization
The health resource utilization questionnaire asks
participants to report the following visits over a speci-
fied time period: 1) health care professionals; 2) admis-
sions or visits to hospital; and 3) laboratory work. The
health resource utilization questionnaire has been pre-
viously described and supported in previous studies
[48]. We will estimate total health care related costs
over the 12 months from a Canadian health care sys-
tem perspective. Participants will be instructed to spe-
cify total health care expenditure and report the
reason for each item. Additionally, participants will be
instructed to report health care expenditure due to any
adverse events associated with the aerobic-based train-
ing program; this is not anticipated to be a major cost
driver. On a per participant basis, costs will be
assigned to health care resource utilization using a
fully allocated hospital cost model (for in-patient costs)
and the British Columbia provincial guide to medical
fees (for outpatient costs). Our base case analysis will
consider the costs of all health care resource use and
our sensitivity analyses will include only intervention




Participants will be randomly assigned (1:1) to either the
aerobic-based exercise training (AT) group or the usual
care (CON) group. The randomization sequence will be
generated by a central, web-based randomization service
http://www.randomization.net; permuted blocks of vary-
ing size will be employed to ensure balance over time.
After baseline assessment, research personnel not
involved in measurement or intervention will access the
web-based randomization service to determine the
group allocation.
Allocation Concealment
Recruitment and enrolment of participants will be man-
aged by the research coordinator who will screen for
study eligibility, obtain informed consent, and conduct
baseline assessment. Following completion of baseline
assessment, the research coordinator will access the
web-based randomization service and the participant
will be assigned a participant number and allocated to
the intervention or the control group. Research person-
nel performing the outcome assessment and data analy-
sis will be blinded to group allocation but it is not
possible to blind participants and personnel delivering
interventions to group allocation.
Experimental Groups
Aerobic-Based Training (AT) Group
All AT group classes will be led by instructors certified
to instruct seniors. Each 60-minute class will include a
10 minute warm-up, a target of 40 minutes of walking,
and a 10-minute cool down. Class attendance will be
recorded for each participant by the instructors
throughout the six-month intervention period.
Over the six month intervention period, we will use
three complimentary techniques to monitor and pro-
gress exercise intensity of the AT program. Each partici-
pant will:
1) Wear a heart rate monitor and will be asked to
work initially at approximately 40% of his/her age speci-
fic target heart rate (i.e., heart rate reserve; HRR) and
gradually progress to reach the target of 60% of HRR.
Once the target of 60% of HRR is achieved, it will be
sustained by the participant for the remainder of the
intervention period;
2) Subjectively monitor the intensity of each workout
using the Borg’s Rating of Perceived Exertion (RPE)
[49]. Participants will be gradually progressed to a target
RPE of 14 to 15; and
3) Use the simple “talk” test [50,51]. Participants will
be asked to initially walk at a pace where they can con-
verse comfortably without effort and gradually progress
to a pace where conversation requires a bit of effort.
In addition to the formal group classes, all individuals
in the AT group will be given a pedometer to serve as
both an incentive and reminder to partake in walking
on a daily basis. Participants will be asked to record the
number of steps each day. All pedometers will be
returned to the study coordinator at the 6 month assess-
ment session.
Usual Care (CON) Group
Participants in the CON group will receive educational
material about vascular cognitive impairment and about
stress management, healthful diet, and smoking. How-
ever, this group will not receive specific information
regarding physical activity. Participants in the AT group
will also be offered these educational materials.
Adverse Events Monitoring
Dr. Philip Lee, in addition to a physician and statistician
external to the research team, will review all adverse
events reported in the study on a monthly basis. They
will inform us to stop the study if the adverse events
data are of sufficient concern.
Statistical Analyses
As a primary objective of this study is to provide preli-
minary evidence of efficacy we will compare partici-
pants of the AT group who are compliant with the
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cise sessions) to the CON group rather than using an
intention-to-treat analysis as would be appropriate in a
pivotal clinical trial. In addition, no adjustment for mul-
tiple endpoints will be made since in a proof-of-concept
study a Type II error is of more concern than a Type I
error [52]. For each of the three primary endpoints (i.e.,
ADAS-Cog, EXIT-25, ADCS-ADL), the change from
baseline to six months and 12 months will be assessed
using an analysis of covariance model incorporating the
baseline measurement. Observing a statistically signifi-
cant difference on any of the three primary outcomes
will be considered preliminary evidence of efficacy.
We will also report variances, co-variances, and effect
sizes, as well as sampling feasibility (i.e., ease of recruit-
ment, recruitment rate, withdrawal rate). This informa-
tion will inform sampling for future trials.
Economic Analysis
Our economic evaluation will explore incremental costs
and health benefits comparing the aerobic-based train-
ing intervention with usual care using both cost effec-
tiveness and cost utility analyses. A cost utility analysis
is a specific type of cost effectiveness analysis where
health benefits are measured using QALYs. The out-
come of our cost effectiveness analysis is the incremen-
tal cost effectiveness ratio (ICER). By definition, an
ICER is the difference between the mean costs of pro-
viding the competing interventions divided by the differ-
ence in effectiveness, where ICER = Δ Cost/Δ Effect
[53]. We will determine the incremental cost of the
aerobic-based training intervention per person experien-
cing a clinically significant improvement in cognitive
performance relative to usual care. Further, for our cost
utility analysis, we will estimate the incremental cost per
quality adjusted life year gained (QALY). We will use a
combination of imputation and bootstrapping to quan-




Recruitment will commence in December 2009. Final
follow-up assessment is expected to conclude in Febru-
ary 2012.
Discussion
Although exercise therapy holds promise for delaying
the onset and slowing down the progression of both
cognitive and functional decline, very few randomized
controlled trials of exercise have been conducted in
populations at high-risk for dementia [30]. This research
will be an important first step in quantifying the effect
of an exercise intervention on cognitive and daily func-
tion among seniors with SIVCI, as vascular cognitive
impairment is the second most common cause of
dementia in older adults [1-4]. Exercise has the potential
to be an effective, inexpensive, and accessible interven-
tion strategy with minimal adverse effects. Retarding the
rate of cognitive decline among seniors with SIVCI
could preserve independent functioning and quality of
life in this population. This, in turn, could lead to
reduced health care utilization costs and avoidance of
early institutional care. Delaying the onset or retarding
the progression of dementia by only one year would
reduce the number of clinical cases of dementia by 9.2
million by 2050 in the US alone [54].
Our interdisciplinary research team will use a multi-
pronged approach to explore the utility of aerobic-based
exercise training among seniors with mild SIVCI. The
impact of our proposed work may be significant for
seniors with mild SIVCI.
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